Search company, investor...
ROME Therapeutics company logo

ROME Therapeutics

Founded Year



Series B | Alive

Total Raised


Last Raised

$77M | 1 yr ago

About ROME Therapeutics

ROME Therapeutics is developing therapies for cancer and autoimmune diseases by harnessing the power of the repeatome - vast stretches of uncharted genetic material that have long been dismissed as "junk DNA". With several drug targets identified and multiple discovery programs underway, ROME is moving to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of leaders across fields including oncology, immunology, virology, and machine learning.

Headquarters Location

610 Main Street

Cambridge, Massachusetts, 02139,

United States

Missing: ROME Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ROME Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing ROME Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned ROME Therapeutics in 1 CB Insights research brief, most recently on Apr 30, 2020.

Expert Collections containing ROME Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ROME Therapeutics is included in 3 Expert Collections, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Biopharma Tech

838 items

Latest ROME Therapeutics News

ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease

Nov 10, 2022

Company to share preclinical data from lead program in autoimmune disease at American College of Rheumatology (ACR) Convergence 2022 November 10, 2022 06:30 AM Eastern Standard Time BOSTON--( BUSINESS WIRE )-- ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for cancer and autoimmune diseases, today announced it will share preclinical data from its lead program, a LINE-1 reverse transcriptase inhibitor, in a poster presentation at American College of Rheumatology (ACR) Convergence 2022, taking place November 10 – 14, 2022, in Philadelphia. LINE-1 reverse transcriptase is an endogenous reverse transcriptase (eRT) encoded by repetitive sequences in the human genome. eRTs convert RNA into DNA in the cytosol, triggering a viral mimicry response via nucleic acid-sensors, such as cGAS, resulting in activation of Type 1 interferon and NFκB pathways. Since excess activation of these pathways can lead to autoimmune disease, eRT inhibitors have great potential to improve pathological outcomes. Through rational structure-based drug design, ROME identified novel, selective and potent inhibitors of LINE-1 reverse transcriptase. The data show that ROME’s compound inhibited a Type 1 interferon response in multiple in vivo and in vitro models of autoimmune disease. “Endogenous reverse transcriptases encoded by repetitive sequences in the human genome are increasingly implicated in many difficult-to-treat diseases, including autoimmune disease. At ROME we have identified first-of-their-kind selective inhibitors of LINE-1 endogenous reverse transcriptase, a target that triggers inflammatory responses,” said Dennis Zaller, Ph.D., Chief Scientific Officer of ROME. “We are excited to share new preclinical data demonstrating that our LINE-1 reverse transcriptase inhibitor effectively blocks inflammatory Type 1 interferon responses that drive many intractable autoimmune diseases. This demonstrates the promise of therapeutic targets within the dark genome, and we look forward to advancing this program with the goal of offering a new treatment option for diseases with great unmet need.” Details of the poster presentation are as follows: Abstract #1698

ROME Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ROME Therapeutics Rank

ROME Therapeutics Frequently Asked Questions (FAQ)

  • When was ROME Therapeutics founded?

    ROME Therapeutics was founded in 2020.

  • Where is ROME Therapeutics's headquarters?

    ROME Therapeutics's headquarters is located at 610 Main Street, Cambridge.

  • What is ROME Therapeutics's latest funding round?

    ROME Therapeutics's latest funding round is Series B.

  • How much did ROME Therapeutics raise?

    ROME Therapeutics raised a total of $127M.

  • Who are the investors of ROME Therapeutics?

    Investors of ROME Therapeutics include ARCH Venture Partners, Google Ventures, Casdin Capital, Andreessen Horowitz, Section 32 and 6 more.

  • Who are ROME Therapeutics's competitors?

    Competitors of ROME Therapeutics include TetraGenetics.

Compare ROME Therapeutics to Competitors


selectION is developing a class of medicines to treat autoimmune diseases and other ion channel related disorders.

Calypso Biotech

Calypso Biotech is a biopharmaceutical company that develops monoclonal antibodies for the treatment of immune pathologies with unmet medical needs.

Metrion Biosciences Logo
Metrion Biosciences

Metrion Biosciences is a UK-based Contract Research Organization (CRO) that focuses on delivering a range of ion channel drug discovery services. The company provides electrophysiology screening services to support client medicinal chemistry optimization programs, CiPA compliant cardiac safety profiling assays, neuroscience assays and translational assays.

Kineta Logo

Kineta is a biotechnology company that focuses on developing therapeutics in areas of autoimmune disease, viral disease, and chronic pain. The company was founded in 2008 and is based in Seattle, Washington.

Cue Biopharma Logo
Cue Biopharma

Cue Biopharma engineers with disease-relevant T-cells for the treatment of cancer and autoimmune disease. Its technology platform delivers amplifying or attenuating signals to specific T-cell subsets and address any T-cell-mediated disease. The company was founded in 2014 and is based in Boston, Massachusetts.

Saniona Logo

Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a portfolio of potential drug candidates in pre-clinical and clinical stage including a Phase 3 program for obesity and two Phase 2 programs for metabolic disorders and cocaine addiction, respectively. The research is focused on ion channels – a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona is headquartered in Copenhagen, Denmark, and has ongoing collaboration agreements with a number of external research partners across the world.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.